Strategy for biosimilars in China

Biosimilars/Research | Posted 26/09/2014 post-comment0 Post your comment

China is one of the largest pharmaceutical markets in the world, and has seen rapid growth in the biopharmaceuticals industry in recent years.  However, it is still lacking guidance when it comes to biosimilars. Authors Li and Tuan from the Shenyang Pharmaceutical University, China, discuss how this affects biologicals companies in China [1].

Guidance V13F21

A whopping 361 of the 382 biologicals approved in China are ‘copy biologicals’. Domestic ‘copy biologicals’ have been on the market in China for 20 years, according to data from the Southern Medicine Economic Research Institute (SMEI) of the China State Food and Drug Administration (SFDA) [2]. However, despite this fact, the country has yet to release biosimilars guidance. It was stated that a new Drug Registration Regulation, which would include biosimilars, would be released by the SFDA after the 18th National Congress of the Communist Party, which was held in Beijing on 8–14 November 2012, however, as yet nothing has emerged.

Problems for China’s biologicals industry include the fact that the scale of China’s biological companies is mostly small and medium, and their single financing channels lead to a shortage of funds for research and development.

In recent years, with more biologicals patents expiring, companies have simultaneously chosen the same reference monoclonal antibodies to imitate. This repeated investment of small-scale domestic enterprises has caused a huge waste of resources, resulting in low profit margins for ‘copy biologicals’ in China.

Another problem is the lack of a clear policy for biosimilars in China, with no definition of biosimilars or guidance is yet to release. The 2007 edition of the ‘Drug Registration’ Article XII declared that biological drug applications should be in accordance with new drug applications, with no mention of biosimilars.

Authors Li and Tuan therefore urge the Chinese Government to develop national policies and regulations for biosimilars ‘as soon as possible’. They also call on biologicals companies to ‘actively expand’ their financing channels and ‘strengthen cooperation with research institutions’ in order to increase innovation, while encouraging them to re-structure in order to enhance competitiveness.

The authors conclude that China, as a country that has embraced generics, should now grab the opportunity to develop biosimilars. They therefore urge the government to enact guideline principles for biosimilars soon, to fuel the biosimilars industry in China.

Conflict of interest
The authors of the research paper [1] did not declare any conflicts of interest.

Editor’s comment
It should be noted that ‘copy biologicals’ approved in China might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Readers interested in contributing a research or perspective paper toGaBI Journal– an independent, peer reviewed academic journal platform – please send us your submission here.

Related articles
The generics market in China

China set to give a big boost to biologics

References
1.   Li Y, Tian L. Biosimilars: Current Status and Countermeasures. Asian Journal of Social Pharmacy. 2014;9(2):60-3.
2.   GaBI Online - Generics and Biosimilars Initiative. China to release biosimilars guidelines [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Sep 26]. Available from: www.gabionline.net/Guidelines/China-to-release-biosimilars-guidelines

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro PharmaCommunications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Federal purchases of biological drugs for cancer in Brazil
Cancer Cell V13I20
Biosimilars/Research Posted 24/09/2021
Clinical development of biosimilars in the oncology setting
Cancer image015
Biosimilars/Research Posted 17/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010